Gene-to-Patient Integrated Solutions for Cell Therapy

Whether autologous or allogeneic, CAR-T or any number of cell types, cell therapy development and manufacturing require unique expertise and accelerated timelines to address patient needs. With over a decade of expertise across the gene-to-patient process from critical raw materials to clinical trial supply, Catalent is a premier cell therapy CDMO offering integrated solutions for successful cell therapy development, scale-up, and manufacturing.

Catalent’s cell therapy global network provides expertise across the entire journey from pre-clinical to commercial launch, from our iPSC expertise in Dusseldorf, Germany, to process and analytical development in Gosselies, Belgium, to clinical and commercial manufacturing in Gosselies and Princeton, New Jersey, all under one CGMP umbrella. We are dedicated to expanding our capacity and capabilities within a dynamic market to meet the growing demands of our customers.

From early risk-assessment to viral vector production for gene-enabled cell therapies, along with custom analytical development and manufacturing services, our scalable and commercially-ready solutions across autologous and allogeneic modalities help accelerate your path to market within an agile CGMP infrastructure. Additionally, our Clinical Supply Services team is prepared to support the future delivery of your product to the clinic.

Our teams are committed to addressing the gaps that exist within both autologous and allogeneic cell therapy development and manufacturing. As unique as the therapies themselves, every path from the bench to the clinic is tailored to ensure that your results are timely and efficient. We optimize the supply chain per the needs of your specific cell type and treatment type and streamline the manufacturing process for optimal cell potency. Our best-in-class manufacturing facilities and scientific know-how give our customers an advantage in reducing the complexities of bringing a cell therapy to market faster.